As it is known that Aβ senile plaque pathology can hasten the formation of tau pathology in mouse models of AD (38, 39), BACE1 inhibitors are predicted to reduce plaque-mediated enhancement of tau pathology. Here, MAPT is linked to Alzheimer disease.